Abstracts Archive - Page 366 of 2607 - ACR Meeting Abstracts

Abstract Number: 1051 • ACR Convergence 2023
Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis
sibel aydin¹, seyyid acikgoz², Ummugulsum Oguz³, antonio Vieira⁴, patrick Leclerc⁴, Suharsh Shah⁴, Lihi Eder⁵ and Gurjit S Kaeley⁶, ¹University of Ottawa - Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada, ⁵Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being shown repeatedly, several barriers persist and stand in the way of…
Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Denis Krutko¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵, Grant Cannon⁶ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
Abstract Number: 1055 • ACR Convergence 2023
Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort
Vanissa Savarimuthu¹, Alexandra Ladouceur², Oliver Terry¹, Janet Roberts³, Janet Pope⁴, Thomas Appleton⁴, Sabrina Hoa⁵, Aurore Fifi-Mah⁶, Nancy Maltez⁷, Alexandra Saltman⁸, Megan Himmel⁸, Ines Colmegna⁹, Lindsay Cho¹⁰, Emma Schmidt¹⁰, Claudie Berger¹¹, Thomas Barnetche¹², Lourdes Gonzalez Arreola¹³, Carrie Ye¹⁴, Shahin Jamal¹⁵ and Marie Hudson¹⁶, ¹McGill University, Montreal, QC, Canada, ²Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Montreal, Brossard, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷The Ottawa Hospital, Ottawa, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, BC, Canada, ¹¹RI-MUHC, Montreal, QC, Canada, ¹²Bordeaux University Hospital, Bordeaux, France, ¹³Arthritis Research Canada, Vancouver, BC, Canada, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶McGill University, Montréal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. A drawback of ICI therapy is their off-target effects known as immune-related adverse events…
Abstract Number: 1048 • ACR Convergence 2023
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Seyyid Bilal Acikgoz¹, Ummugulsum Gazel², Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Amin Zahrai⁴, Catherine Ivory⁴, Elliot Hepworth² and sibel aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Ultrasound (US) has emerged as a sensitive method, especially when compared to clinical examination, for evaluating disease activity in Rheumatoid Arthritis (RA). Several studies…
Abstract Number: 1057 • ACR Convergence 2023
Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data
Alexandra Ladouceur¹, Marie Hudson², Hassan Behlouli³, Jeffrey Curtis⁴, Louise Pilote³ and Sasha Bernatsky³, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immune checkpoint inhibitors (ICIs) improve survival in many malignancies1, by augmenting the immune system's anti-tumor response. However, ICI can result in immune-related adverse events…
Abstract Number: 1058 • ACR Convergence 2023
Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors
Alexandra Ladouceur¹, Thomas Barnetche², Sorilla Mary-Prey³, Caroline Dutriaux⁴, Emilie Gerard³, Anne Pham-Ledard³, Marie Beylot-Barry³, Maeva Zysman³, Rémi Veillon³, Charlotte Domblides⁵, Amaury Daste⁵, Marine Gross-Goupil⁵, Baptiste Sionneau⁵, Félix Lefort⁵, Mathieu Larroquette⁵, Christophe Richez⁶, Marie-Elise Truchetet², Thierry Schaeverbebke⁷ and Marie Kostine², ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²Bordeaux University Hospital, Bordeaux, France, ³Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁴CHU-Bordeaux, Bordeaux, France, ⁵Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient's own immune system to fight cancer. However, activation of the immune system…
Abstract Number: 1040 • ACR Convergence 2023
Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT
Juan Molina-Collada¹, Isabel Castrejon², Irene Monjo³, Elisa Fernandez-Fernandez⁴, Gabriela Torres⁵, JULIA MARTINEZ BARRIO⁶, Jose María Alvaro-Gracias⁷ and Eugenio De Miguel⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Gregorio Marañón, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Aortitis is a serious potential complication of patients with giant cell arteritis (GCA) and may lead to dilation, aneurysms or dissection. Since ultrasound (US)…
Abstract Number: 1049 • ACR Convergence 2023
Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA)
Jem Ninan¹, Suellen Lyne¹, Julian McNeil², Joanna Tieu³, Vidya Limaye⁴, Susanna Proudman⁴, Susan Lester³ and Catherine Hill³, ¹University of Adelaide, Adelaide, Australia, ²Modbury Hospital, Modbury, Australia, ³The Queen Elizabeth Hospital, Woodville, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: A previous survey of Australian Rheumatologists indicated low confidence (60% of Australian Rheumatologists) in the use of Temporal artery ultrasound provided by their Radiology…
Abstract Number: 1050 • ACR Convergence 2023
Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols
Fabian Carranza Enriquez¹, Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Mayra Mejia-Avila², Amyrari Vázquez-Ortega³, Paola Flores-Ordoñez², Karina Arias Callejas², Alejandra Enriquez-Luna⁴, Graciliano Ramon-Diaz⁴, Brenda Bravo-Zarate², Tatiana Sofía Rodríguez-Reyna³ and Carlos Pineda⁴, ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Rehabilitacion, Mexico City, Mexico
Background/Purpose: Lung ultrasound (LUS) has proven useful to detect interstitial lung disease (ILD) among patients with SSc when compared to high-resolution computerized tomography (HRCT) as…
Abstract Number: 1052 • ACR Convergence 2023
Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking
Sokratis Apostolidis¹, Kyra Sacksith¹, Bria Fulmer¹, Zoe Quandt², Mark Anderson², Terri Laufer³ and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of California San Francisco, San Franscisco, CA, ³University of Pennsylvania, Philadlephia, PA
Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer…
Abstract Number: 1056 • ACR Convergence 2023
Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Alexandra Ladouceur¹, Gael Mouterde², Alice TISON³, Samuel Bitoun⁴, Sorilla Mary-Prey⁵, Caroline Dutriaux⁶, Emilie Gerard⁵, Anne Pham-Ledard⁵, Marie Beylot-Barry⁵, Maeva Zysman⁵, Rémi Veillon⁵, Charlotte Domblides⁷, Amaury Daste⁷, Marine Gross-Goupil⁷, Baptiste Sionneau⁷, Félix Lefort⁷, Mathieu Larroquette⁷, Thomas Barnetche⁸, Christophe Richez⁹, Marie-Elise Truchetet⁸, Thierry Schaeverbebke¹⁰ and Marie Kostine⁸, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²CHU Lapeyronie, Montpellier, France, ³CHU de la Cavale Blanche, Brest, France, ⁴Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, ⁵Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁶CHU-Bordeaux, Bordeaux, France, ⁷Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁸Bordeaux University Hospital, Bordeaux, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
Abstract Number: 1062 • ACR Convergence 2023
Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Samuel Good¹, Grazyna Adamus², Michael Gorin³, Jordan Jacquez¹, Jennifer Grossman¹, Brian Skaggs¹, Ashira Hasan² and Maureen McMahon⁴, ¹University of California Los Angeles, Los Angeles, CA, ²Oregon Health & Science University, Portland, OR, ³Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Autoimmune retinopathy (AIR) is a disease process in which circulating autoantibodies (AAbs) against retina-specific antigens cause local inflammation and can lead to blindness. Hydroxychloroquine…
Abstract Number: 1061 • ACR Convergence 2023
Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology
Chani-mi Lee¹, Margaret Wang², Aarthi Rajkumar¹, Cassandra Calabrese³ and Leonard Calabrese³, ¹University Hospital, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little is known…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].